475481-99-3

Basic information

• Product Name: 4-CHLOROMETHYL-2-(2-METHOXY-PHENYL)-5-METHYL-OXAZOLE
• Synonyms: 4-CHLOROMETHYL-2-(2-METHOXY-PHENYL)-5-METHYL-OXAZOLE;4-(Chloromethyl)-2-(2-methoxyphenyl)-5-methyl-1,3-oxazole
• CAS NO: 475481-99-3
• Molecular Formula: C₁₂H₁₂ClNO₂
• Molecular Weight: 237.68
• Mol File: 475481-99-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CHLOROMETHYL-2-(2-METHOXY-PHENYL)-5-METHYL-OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROMETHYL-2-(2-METHOXY-PHENYL)-5-METHYL-OXAZOLE(475481-99-3)
• EPA Substance Registry System: 4-CHLOROMETHYL-2-(2-METHOXY-PHENYL)-5-METHYL-OXAZOLE(475481-99-3)

Safety Data

• Hazardous Substances Data: 475481-99-3(Hazardous Substances Data)

Upstream product

• 135-02-4 ortho-anisaldehyde 

Downstream Products

• 1017231-83-2 C₁₃H₁₂N₂O₂ 
• 475480-66-1 [rac]-2-ethoxy-3-{4-[2-(2-methoxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-2-methyl-phenyl}-propionic acid 

Relevant articles and documents

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.

Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

In the quest for novel PPARα/γ co-agonists as putative drugs for the treatment of type 2 diabetes and dyslipidemia, we have used a structure-based design approach to identify propionic acids with a 1,5-disubstituted indole scaffold as potent PPARα/γ activ

Indolyl derivatives as liver-X-receptor (LXR) modulators

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.